iSpecimen Inc. Common Stock
Compare this stock
ISPC Stock Report Card
$
23%
Performance
Score:
10/100
ISPC returned -65.85% in the last 12 months. Based on SPY's performance of 13.09%, its performance is below average giving it a score of 10 of 100.
Sentiment
Score:
61/100
ISPC had a bullish sentiment score of 61.25% across Twitter and StockTwits over the last 12 months. It had an average of 1.00 posts, 0.00 comments, and 0.00 likes per day.
Technicals
Score:
21/100
ISPC receives a 21 of 100 based on 14 indicators. 2 are bullish, 10 are bearish.
Earnings
Score:
10/100
ISPC has missed earnings 7 times in the last 20 quarters.
Profit
Score:
10/100
Out of the last 17 quarters, ISPC has had 0 profitable quarters and has increased their profits year over year on 0 of them.
Volatility
Score:
53/100
ISPC has had a higher than average amount of volatility over the last 12 months giving it a score of 52 of 100.
iSpecimen Inc. Common Stock Summary
Nasdaq / ISPC
Healthcare
Medical - Diagnostics & Research
iSpecimen Inc. provides technology that connects life science researchers who need human biofluids, tissues, and living cells for their research with biospecimens available in healthcare provider organizations worldwide. Its cloud-based technology enables scientists to search for specimens and patients across a network of hospitals, labs, biobanks, blood centers, and other healthcare organizations. The company develops and operates iSpecimen Marketplace, a proprietary online marketplace platform that connects medical researchers who need access to subjects, samples, and data with hospitals, laboratories, and other organizations who have access to them. It serves biopharmaceutical companies, in vitro diagnostic companies, and government/academic institutions. The company was incorporated in 2009 and is headquartered in Lexington, Massachusetts.
Power up your portfolio
Build a portfolio of your favorite stocks
Pluto makes it easy to build investing strategies and automate your portfolio
Checkout Similar Companies
ISPC scored poorly on our reportcard. Here are some similar companies and how they performed.